Mania and Rhabdomyolysis Linked to Chronic Psilocybin Use: Clinical and Policy Lessons

Case Report: Mania and Rhabdomyolysis After Prolonged Daily Psilocybin Use

A peer-reviewed case report published on September 21, 2026 in PubMed (PMID: 42758023) documents an instance of acute mania and rhabdomyolysis in a patient who engaged in long-term, daily psilocybin use. The patient, with no prior diagnosis of bipolar disorder or significant medical comorbidity, presented to emergency care with agitation, pressured speech, insomnia, and markedly elevated creatine kinase levels—hallmarks of mania and muscle breakdown. This report is among the first to directly link chronic, unsupervised psilocybin consumption to these severe adverse outcomes.

Mechanisms and Clinical Context: What Sets Chronic Use Apart?

Unlike the single or infrequent dosing regimens used in clinical trials, chronic daily psilocybin use may trigger physiological and psychiatric complications not previously observed in controlled settings. Psilocybin, a serotonergic psychedelic, is known to act as a partial agonist at the 5-HT2A receptor. While transient increases in heart rate and blood pressure are documented, the development of mania and rhabdomyolysis suggests additional, poorly understood risks with repeated exposure. Rhabdomyolysis, the rapid breakdown of muscle tissue, is rare in psychedelic literature but can result from agitation, hyperactivity, or direct toxic effects. Mania—characterized by elevated mood, impulsivity, and decreased need for sleep—has been reported with serotonergic agents, especially in individuals with undiagnosed mood disorders, but this case involved a patient without such history.

This distinction is critical: clinical trials of psilocybin for depression, PTSD, and other conditions have excluded daily or high-frequency dosing, and participants are closely screened and monitored. The safety profile established in these settings may not extend to unsupervised, chronic use, especially as access to psilocybin expands through decriminalization and medicalization initiatives.

Policy and Research Implications: Dosing Guidance and Surveillance

This case underscores the urgent need for evidence-based dosing guidelines and robust adverse event surveillance as psilocybin transitions from research to broader clinical and community contexts. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada have so far focused on single-dose or session-based protocols, with little guidance for ongoing or self-directed use. The absence of standardized dosing recommendations leaves clinicians and users without clear parameters for safety.

• Public education is essential to counter misconceptions that psilocybin is universally safe, especially given increasing reports of "microdosing" and other non-trial use patterns.
• Clinician training should include recognition of rare but serious complications like mania and rhabdomyolysis, even in patients without psychiatric history.
• Post-market surveillance—including adverse event reporting systems—should be implemented in jurisdictions where psilocybin is accessible outside trials, drawing lessons from pharmacovigilance in other drug classes.

Notably, this case also exposes a gap in current research: few studies have systematically examined the effects of repeated or high-frequency psilocybin exposure, and most trial exclusion criteria specifically preclude such patterns. As a result, real-world risks may be underappreciated, and rare complications may go unreported until they reach clinical attention.

Risks, Unknowns, and the Limits of Current Evidence

While this case report does not establish causality, it highlights plausible mechanisms and risk factors that warrant further investigation. The rarity of rhabdomyolysis in psychedelic literature may reflect underdiagnosis or underreporting, especially outside hospital settings. Similarly, the potential for mania—particularly in individuals with latent bipolar spectrum disorders—remains incompletely characterized, as most clinical trials exclude such populations.

Importantly, the case illustrates a real failure mode: as access to psilocybin expands, individuals may experiment with dosing regimens not validated in research, increasing the risk of idiosyncratic or severe adverse outcomes. This risk is compounded by the proliferation of online dosing guides and anecdotal reports, which often lack clinical oversight or risk mitigation strategies.

Looking Forward: Building a Safer Framework for Psilocybin Access

As psilocybin policy evolves—through decriminalization, medicalization, and ongoing clinical trials—stakeholders must balance enthusiasm for therapeutic potential with vigilance for rare but serious risks. This case report provides a concrete example of complications that may arise outside controlled settings, highlighting the need for:

• Clear, evidence-based dosing guidelines for both clinical and non-clinical contexts
• Mandatory adverse event reporting in jurisdictions permitting psilocybin use
• Expanded research into the effects of chronic and high-frequency use
• Public health campaigns to educate users about potential risks and warning signs

Ultimately, the field must avoid assuming that safety data from controlled trials generalize to all patterns of use. As psilocybin transitions from research to real-world application, rare but severe complications like mania and rhabdomyolysis must inform both policy and practice.

By Dr. Alex R. Jensen, MD, MPH. Reviewed by Dr. Emily Tran, MD, on 2026-09-22. Research based on primary PubMed source (PMID: 42758023), FDA guidelines, and current clinical trial protocols.